Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma.